1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Edge Therapeutics, Inc. - Product Pipeline Review - 2013

Edge Therapeutics, Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 26 pages

Edge Therapeutics, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Edge Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Edge Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Edge Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Edge Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Edge Therapeutics, Inc. - Brief Edge Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Edge Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Edge Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Edge Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Edge Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Edge Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Edge Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Edge Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Edge Therapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Edge Therapeutics, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Edge Therapeutics, Inc. Snapshot 4
Edge Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Edge Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Edge Therapeutics, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Edge Therapeutics, Inc. - Pipeline Products Glance 9
Edge Therapeutics, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Edge Therapeutics, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Edge Therapeutics, Inc. - Drug Profiles 13
EG-1962 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
aminocaproic acid SR 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
EG-1960 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Edge Therapeutics, Inc. - Pipeline Analysis 17
Edge Therapeutics, Inc. - Pipeline Products by Therapeutic Class 17
Edge Therapeutics, Inc. - Pipeline Products by Target 18
Edge Therapeutics, Inc. - Pipeline Products by Route of Administration 19
Edge Therapeutics, Inc. - Pipeline Products by Molecule Type 20
Edge Therapeutics, Inc. - Pipeline Products by Mechanism of Action 21
Edge Therapeutics, Inc. - Recent Pipeline Updates 22
Edge Therapeutics, Inc. - Dormant Projects 23
Edge Therapeutics, Inc. - Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26



List of Tables

Edge Therapeutics, Inc., Key Information 4
Edge Therapeutics, Inc., Key Facts 4
Edge Therapeutics, Inc. - Pipeline by Indication, 2013 6
Edge Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Edge Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Edge Therapeutics, Inc. - Phase II, 2013 9
Edge Therapeutics, Inc. - Phase I, 2013 10
Edge Therapeutics, Inc. - Preclinical, 2013 11
Edge Therapeutics, Inc. - Discovery, 2013 12
Edge Therapeutics, Inc. - Pipeline by Therapeutic Class, 2013 17
Edge Therapeutics, Inc. - Pipeline by Target, 2013 18
Edge Therapeutics, Inc. - Pipeline by Route of Administration, 2013 19
Edge Therapeutics, Inc. - Pipeline by Molecule Type, 2013 20
Edge Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2013 21
Edge Therapeutics, Inc. - Recent Pipeline Updates, 2013 22
Edge Therapeutics, Inc. - Dormant Developmental Projects,2013 23



List of Figures

Edge Therapeutics, Inc. - Pipeline by Top 10 Indication, 2013 6
Edge Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Edge Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Edge Therapeutics, Inc. - Pipeline by Top 10 Therapeutic Class, 2013 17
Edge Therapeutics, Inc. - Pipeline by Top 10 Target, 2013 18
Edge Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2013 19
Edge Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2013 20
Edge Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2013 21



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.